What is Wedbush’s Estimate for STOK FY2029 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Analysts at Wedbush issued their FY2029 EPS estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Tuesday, January 7th. Wedbush analyst L. Chico forecasts that the company will post earnings of ($0.41) per share for the year. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million.

STOK has been the topic of several other reports. Chardan Capital started coverage on Stoke Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $24.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Leerink Partners started coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 price target for the company. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Stoke Therapeutics currently has an average rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $9.00 on Thursday. The business’s fifty day moving average price is $11.91 and its two-hundred day moving average price is $13.04. The stock has a market cap of $476.70 million, a PE ratio of -4.29 and a beta of 0.95. Stoke Therapeutics has a one year low of $4.09 and a one year high of $17.58.

Institutional Investors Weigh In On Stoke Therapeutics

Large investors have recently made changes to their positions in the business. Exome Asset Management LLC purchased a new stake in Stoke Therapeutics during the 3rd quarter worth $2,170,000. Barclays PLC boosted its position in shares of Stoke Therapeutics by 145.3% in the third quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after buying an additional 47,239 shares during the period. Geode Capital Management LLC grew its stake in shares of Stoke Therapeutics by 9.7% in the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock valued at $10,705,000 after buying an additional 76,661 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Stoke Therapeutics by 338.2% during the 3rd quarter. Jane Street Group LLC now owns 330,442 shares of the company’s stock valued at $4,061,000 after buying an additional 255,028 shares during the period. Finally, State Street Corp lifted its position in Stoke Therapeutics by 8.6% during the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after acquiring an additional 137,145 shares in the last quarter.

Insiders Place Their Bets

In related news, General Counsel Jonathan Allan sold 9,696 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the completion of the sale, the general counsel now owns 35,142 shares of the company’s stock, valued at approximately $449,114.76. This represents a 21.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Barry Ticho sold 2,586 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $33,592.14. Following the completion of the transaction, the insider now owns 44,746 shares in the company, valued at $581,250.54. The trade was a 5.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock valued at $809,421 over the last quarter. Company insiders own 11.30% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.